Clinical Trial

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall purpose of this project is to answer the following clinical question: Among Medication-Related Osteonecrosis of the Jaw (MRONJ) patients, do those who are treated with the Pentoxifylline and Tocopherol (PENTO) regimen and standard of care, when compared to those treated with standard of care alone, have decreased areas of exposed bone after one year of treatment?
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-02-01; most recent amendment 2026-04-27.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-04-27
Status change: Recruiting → Enrolling by Invitation 2020-05-01
Status change: Not Yet Recruiting → Recruiting 2018-04-24
Trial Details
NCT Number NCT03040778
Lead Sponsor University of Washington
Collaborators: University of Alabama at Birmingham, New York Center for Orthognathic and Maxillofacial Surgery, University of Michigan
Conditions Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Enrollment 100 participants
Start Date 2018-04-01
Primary Completion 2026-05 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29